The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
- Pfizer Japan Voluntarily Recalls Generic Gemcitabine
March 23, 2015
- Opicapone Reduces Off-Time by 2 Hours in Parkinson’s Disease Patients as Add-On to Levodopa: Ono
March 20, 2015
- Daiichi Sankyo, AZ to Copromote Constipation Treatment Movantik in US
March 20, 2015
- Astellas Files Kiklin to Treat Non-Dialysis CKD Patients
March 18, 2015
- MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
- Alirocumab Meets Primary Efficacy Endpoint in PIII Study: Sanofi
March 17, 2015
- Minophagen Seeks Approval for CTCL Treatment
March 17, 2015
- Selexipag Lowers Risk of Morbidity, Mortality Events by 40% in PIII Study
March 17, 2015
- AnGes MG Initiates PIII Study of Nucleotide NF-κB Decoy Oligo for Atopic Dermatitis
March 17, 2015
- ViiV Receives Approval for HIV Infection Treatment Triumeq
March 17, 2015
- Takecab Surged to Top Spot in January Anterio Ranking
March 16, 2015
- Meiji Seika Halts Development of Antiallergic Treatment, Terminating Pact with Amalyte
March 16, 2015
- Eisai Revises Deal with Epizyme on Cancer Therapies
March 13, 2015
- Santen Earns Approval for Preservative-Free Glaucoma Eye Drops
March 13, 2015
- Sanwa Kagaku Names Hata as Successor to Late President Yamamoto
March 13, 2015
- AZ Appoints BMKK’s Taniguchi as Head of R&D
March 13, 2015
- AZ Receives Approval for Bydureon Pen Formulation
March 13, 2015
- Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers
March 13, 2015
- Takeda Transfers HPV Vaccine License to Kaketsuken
March 12, 2015
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…